Trastuzumab Deruxtecan for HER2-Mutant Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
J. Clin. Oncol 2023 Sep 11;[EPub Ahead of Print], K Goto, Y Goto, T Kubo, K Ninomiya, SW Kim, D Planchard, MJ Ahn, EF Smit, AJ de Langen, M Pérol, E Pons-Tostivint, S Novello, H Hayashi, J Shimizu, DW Kim, CH Kuo, JC Yang, K Pereira, FC Cheng, A Taguchi, Y Cheng, W Feng, Z Tsuchihashi, PA JänneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.